Literature DB >> 19696967

Rapid and sustained response of an intra- and extracranial large cell lymphoma mass to liposomal intrathecal Ara-C and R-MegaCEOP systemic chemotherapy.

Lorenzo Falchi1, Marco Gunnellini, Laura Franco, Patrizia Ferrazza, Stefano Ascani, Anna Marina Liberati.   

Abstract

Prognosis of patients suffering from secondary central nervous system (CNS) lymphoma is dismal. Intracranial spread of a lymphoma arising in adjacent extranodal tissues is a rare event. A 32-year-old patient was diagnosed with progressive diffuse large B-cell lymphoma (DLBCL) with extra- and intracranial localization. He complained of headache, left diplopia, marked rigidity of the neck muscles, and difficulty in swallowing and articulating words, caused by bilateral palsy of the XII cranial nerve. Computed tomography (CT) and positron emission tomography (PET) scans showed disease localizations in the occipital-cervical soft tissue, and cerebellar parenchyma. Due to the severity of the clinical picture, high-dose dexamethasone was immediately administered. Mild improvement was observed during the first 2 days of treatment, but dramatic reduction of symptoms and nerve palsy was documented only in the 48 h after the first intrathecal administration of liposomal Ara-C. Systemic R-MegaCEOP chemotherapy was started 7 days later. Concomitant intrathecal liposomal Ara-C injections were continued for a total of nine administrations during the eight cycles of immunochemotherapy without any toxicity observed. Interim and post-therapy PET showed complete resolution of radionuclide accumulation in the involved sites. Consolidation radiotherapy (36 Gy) was administered in involved areas after the completion of the immunochemotherapy program. At the time of writing, no cumulative neurotoxicity is evident at follow-up of 17 months from diagnosis and 9 months after the overall therapeutic program has been accomplished.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19696967     DOI: 10.1007/s11060-009-9985-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  18 in total

1.  Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis.

Authors:  N Keldsen; W Michalski; S M Bentzen; K B Hansen; K Thorling
Journal:  Acta Oncol       Date:  1996       Impact factor: 4.089

2.  Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Authors:  V Boehme; S Zeynalova; M Kloess; M Loeffler; U Kaiser; M Pfreundschuh; N Schmitz
Journal:  Ann Oncol       Date:  2006-10-03       Impact factor: 32.976

Review 3.  Central nervous system-directed preventative therapy in adults with lymphoma.

Authors:  Andrew McMillan
Journal:  Br J Haematol       Date:  2005-10       Impact factor: 6.998

4.  Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system.

Authors:  Kristoph Jahnke; Eckhard Thiel; Peter Martus; Stefan Schwartz; Agnieszka Korfel
Journal:  Ann Hematol       Date:  2005-08-13       Impact factor: 3.673

5.  High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement.

Authors:  Yvette L Kasamon; Richard J Jones; Steven Piantadosi; Richard F Ambinder; Ross A Abrams; Michael J Borowitz; Candis Morrison; B Douglas Smith; Ian W Flinn
Journal:  Biol Blood Marrow Transplant       Date:  2005-02       Impact factor: 5.742

6.  Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte.

Authors:  C Haioun; C Besson; E Lepage; C Thieblemont; D Simon; C Rose; H Tilly; A Sonet; P Lederlin; M Attal; J Brière; F Reyes
Journal:  Ann Oncol       Date:  2000-06       Impact factor: 32.976

Review 7.  Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature.

Authors:  H Pels; H Schulz; U Schlegel; A Engert
Journal:  Onkologie       Date:  2003-08

8.  Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model.

Authors:  A Hollender; S Kvaloy; O Nome; E Skovlund; K Lote; H Holte
Journal:  Ann Oncol       Date:  2002-07       Impact factor: 32.976

Review 9.  Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities.

Authors:  Yok-Lam Kwong; Dominic Y M Yeung; Joyce C W Chan
Journal:  Ann Hematol       Date:  2008-12-03       Impact factor: 3.673

Review 10.  Treatment of CNS dissemination in systemic lymphoma.

Authors:  B Gleissner; M Chamberlain
Journal:  J Neurooncol       Date:  2007-02-28       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.